These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11362547)

  • 1. The National Task Force on AIDS Drug Development: a progress report.
    Levin J
    BETA; 1995 Jun; ():62-3. PubMed ID: 11362547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA reform: activists' proposals. Food and Drug Administration.
    James JS
    AIDS Treat News; 1995 Aug; (no 228):6-8. PubMed ID: 11362628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reform at FDA: faster access to promising drugs? Food and Drug Administration.
    Baker R
    BETA; 1995 Jun; ():39-40. PubMed ID: 11362545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS drugs & the pharmaceutical industry: a need for reform.
    Griffin MT
    Am J Law Med; 1991; 17(4):363-410. PubMed ID: 1812767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Federal AIDS policy issues today.
    James JS
    AIDS Treat News; 1997 Aug; (No 276):2-8. PubMed ID: 11364520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The growing debate over FDA reform. Food and Drug Administration.
    Link D
    GMHC Treat Issues; 1996 Jan; 10(1):1-5. PubMed ID: 11363372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA reform in Congress: AIDS community absent. Food and Drug Administration.
    James JS
    AIDS Treat News; 1995 Apr; (no 220):4-5. PubMed ID: 11362320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AIDS task force grapples with faster access to protease drugs.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1995 Mar; 1(2):6-11. PubMed ID: 11362314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the FDA in the effort against AIDS.
    Young FE
    Public Health Rep; 1988; 103(3):242-5. PubMed ID: 3131814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contraceptive development--the view from the U.S.A. in the mid 80s].
    Potts M; Siemens A; Burton N
    Contracept Fertil Sex (Paris); 1986 Mar; 14(3):247-51. PubMed ID: 12268061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA reform floated in DC. Food and Drug Administration.
    Hodel D
    GMHC Treat Issues; 1995 Jun; 9(6):6-7. PubMed ID: 11362691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whatever happened to expanded access?
    Notes Undergr; 1997; (No 35):2-3. PubMed ID: 11364564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The application of the patent laws to the drug approval process.
    Coggio BD; Cerrito FD
    Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
    [No Abstract]   [Full Text] [Related]  

  • 17. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
    Chodock R; Yolkut D; Connolly DR
    Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
    Lovell MC
    Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.